Time WILL tell. There are so many unexplored options for Vascepa and I think, for some reason, that Amarin as a company had a bad reputation/lost respect among the pharmaceutical industry. But, hopefully, with new players who hopefully have less self-serving motivation or do not make their self-serving focus so obvious, can maybe repair the view of Amarin and, more importantly, Vascepa, as a valuable asset in medical care.
That’s my hope anyway.
Market Data 
Markets 
AI
